Moderna says COVID-19 vaccine 96 percent effective in teens

Moderna on Thursday released the results of its COVID-19 vaccine trials for those aged 12 to 17, reporting it 96 percent effective against the virus.

The vaccine manufacturer said its trial, involving 3,235 participants, recorded 12 COVID-19 cases that emerged beginning 14 days after the first dose. The company said it had not identified any serious safety concerns to date.

The results of the adolescent trial come as the Food and Drug Administration (FDA) is expected to give emergency use authorization for the Pfizer-BioNTech vaccine to be used among 12- to 15-year-olds in the coming days.